S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)

[1]  D. Lavelle,et al.  The Role of DNA Damage/Stress Response Pathways in the Mechanism of Action of Decitabine , 2008 .

[2]  Y. Saunthararajah,et al.  Clinical effectiveness of decitabine in severe sickle cell disease , 2008, British journal of haematology.

[3]  J. Dipersio,et al.  Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) , 2008, Cancer Chemotherapy and Pharmacology.

[4]  Y. Saunthararajah,et al.  DNA methylation and mechanism of action of 5-azacytidine. , 2008, Blood.

[5]  C. Lowrey,et al.  Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. , 2007, Blood.

[6]  Y. Saunthararajah,et al.  Oral decitabine reactivates expression of the methylated γ‐globin gene in Papio anubis , 2007 .

[7]  Gangning Liang,et al.  Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. , 2007, Cancer research.

[8]  B. Pace,et al.  Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves gamma-globin activation by CREB1 and ATF-2. , 2006, Blood.

[9]  D. Lavelle,et al.  Effect of 5-aza-2′-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the ɛ-, γ-, and β-globin promoters in Papio anubis , 2006 .

[10]  Y. Saunthararajah,et al.  DNA hypo‐methylating agents and sickle cell disease , 2004, British journal of haematology.

[11]  R. Hoffman,et al.  Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.

[12]  D. Lavelle,et al.  Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. , 2002, Blood.

[13]  R. Hoffman,et al.  2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. , 2000, Blood.

[14]  J. Jost,et al.  A bisulfite method of 5-methylcytosine mapping that minimizes template degradation. , 1995, Analytical biochemistry.

[15]  G. Rodgers,et al.  Mortality in sickle cell disease. , 1994 .

[16]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[17]  E Vichinsky,et al.  Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.

[18]  R. Molokie,et al.  Tetrahydrouridine, cytidine analogues, and hemoglobin F , 1985, American journal of hematology.

[19]  G. Stamatoyannopoulos,et al.  Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B. Fisher,et al.  Studies on abnormal hemoglobins. V. The distribution of type S, sickle cell, hemoglobin and type F, alkali resistant, hemoglobin within the red cell population in sickle cell anemia. , 1951, Blood.

[21]  A. Chernoff,et al.  Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. , 1951, Blood.

[22]  Y. Saunthararajah,et al.  Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. , 2007, American journal of hematology.

[23]  A. Migliaccio,et al.  In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. , 2002, Blood cells, molecules & diseases.

[24]  C. Amione,et al.  Reversed-phase high-performance liquid chromatography of human haemoglobin chains. , 1985, Journal of chromatography.